Glycomine

About Glycomine

Glycomine is a biotechnology company focused on developing replacement therapies for rare genetic diseases, aiming to deliver meaningful improvements in quality of life for patients, caregivers, and families.

Products & Services

GLM101:A mannose-1-phosphate replacement therapy in clinical development for the treatment of PMM2-CDG, a rare genetic disease of glycosylation. It is currently in clinical trials in the U.S. and Europe.

Specialties

Replacement therapies for rare genetic diseases Treatment for PMM2-CDG Clinical development of mannose-1-phosphate therapies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series C T: - FT: Series C	A: 115000000 MR: - FA: 115 million FAN: 115000000	D: 2025-04-16 FD: 2025-04-16	11 investors

Series C Latest

2025-04-16

$115.0M

11 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Steven Axon

Chief Executive Officer

H

Hicham Alaoui

Chief Scientific Officer

R

Rose Marino

Chief Medical Officer

P

Peter McWilliams, Ph.D.

CHIEF BUSINESS OFFICER

G

Geoffrey Hird

CHIEF TECHNOLOGY OFFICER

J

Joshua Grass

Chairperson

View 15 more team members with Pro

Unlock Full Team Directory

Recent News

Glycomine Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised